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ABSTRACT 1 
BACKGROUND: A high proportion of patients with remitted major depressive disorder 2 
(MDD) will experience recurring episodes, whilst some develop resilience and remain in 3 
recovery. The neural basis of resilience to recurrence is elusive. Abnormal resting-state 4 
connectivity of the subgenual cingulate cortex (sgACC) was previously found in cross-5 
sectional studies of MDD suggesting its potential pathophysiological importance. The current 6 
study aimed to investigate whether resting-state connectivity to a left sgACC seed region 7 
distinguishes resilient patients from those developing recurring episodes. 8 
METHODS: Forty-seven medication-free remitted MDD patients and 38 healthy controls 9 
underwent resting-state fMRI at baseline. Over 14 months, 30 patients remained resilient 10 
whilst 17 experienced a recurring episode. 11 
RESULTS: Attenuated interhemispheric left-to-right sgACC connectivity distinguished the 12 
resilient from the recurring episode and control groups and was not correlated with residual 13 
depressive symptoms. 14 
CONCLUSIONS: The current study revealed a neural signature of resilience to recurrence 15 
in MDD and thereby elucidates the role of compensatory adaptation in sgACC networks. 16 
 17 
18 
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INTRODUCTION 1 
Major depressive disorder (MDD) is recurrent in a large proportion of patients, whilst 2 
some patients develop resilience after recovering from a major depressive episode (MDE; 3 
(American Psychiatric Association 2000)). The neural basis of resilience to recurrent MDEs 4 
is poorly understood. There is therefore an urgent need to characterize the neural bases of 5 
resilience and, relatedly, vulnerability to recurrence to improve stratification of patients and 6 
to identify novel targets for therapeutic interventions. Resting-state fMRI, frequently used to 7 
measure low frequency fluctuations in blood-oxygen-level dependent (BOLD) signal (Fox et 8 
al. 2007), is particularly promising for understanding the neural basis of resilience from the 9 
perspective of network models of MDD (Seminowicz et al. 2004; Price et al. 2010). 10 
Abnormal functional connectivity within subgenual cingulate cortex (sgACC) networks 11 
has been demonstrated repeatedly in cross-sectional studies of MDD (Greicius et al. 2007; 12 
Sheline et al. 2010; Gaffrey et al. 2012; Herringa et al. 2013; Dutta et al. 2014) and this 13 
region is thought to play a central role in the pathophysiology of MDD (Dunlop et al. 2014). 14 
In a cross-sectional activation fMRI study, our group reported lower functional connectivity 15 
between an anterior temporal lobe (ATL) seed region and the sgACC during the experience 16 
of guilt (self-blame) relative to indignation (other-blame) in remitted MDD (rMDD) patients 17 
compared to a HC group (Green et al. 2012). In a subsequent prospective activation fMRI 18 
study by our group, functional connectivity between these regions was higher during self-19 
blame in rMDD patients who subsequently developed a recurring episode (Lythe et al. 2015) 20 
compared with those who remained stable and with a HC group. Taken together, this led to 21 
the hypothesis that the lower self-blame-selective ATL connectivity in rMDD patients seen in 22 
the first study (Green et al. 2012) reflected a signature of resilience rather than vulnerability 23 
as was initially thought (Lythe et al. 2015). This was based on the observation that the cross-24 
sectional study included a large proportion of MDD patients in full recovery for more than 25 
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one year as well as a large proportion of first episode patients (Green et al. 2012). When 1 
investigating ATL-sgACC functional connectivity irrespective of psychological condition 2 
(i.e., self-blame vs. other-blame), however, there was no evidence of abnormalities in either 3 
the resilient or the recurring episode MDD groups (Lythe et al. 2015). These activation fMRI 4 
data precluded a more systematic investigation of sgACC network connectivity that included 5 
regions other than the ATL. This is because for activation fMRI-based connectivity models, 6 
the selection of seed regions that show different levels of average activation during the 7 
psychological conditions of interest are problematic because of confounding co-activation 8 
and connectivity (Friston et al. 1997). Since the sgACC region displays higher activation in 9 
guilt-prone individuals during self-blame relative to other-blame (Zahn et al. 2009a; Zahn et 10 
al. 2009b; Green et al. 2012), it could not be used as a seed region in our previous activation 11 
fMRI-based connectivity studies. In contrast, resting state fMRI-based connectivity does not 12 
suffer from this limitation and is therefore well-suited to mapping sgACC networks 13 
underpinning resilience more systematically. Furthermore, the acquisition of resting-state 14 
fMRI has some important advantages for clinical neuroimaging investigations since scans can 15 
be acquired relatively quickly (less than 10 minutes) and without needing to implement and 16 
interpret complex psychological paradigms. 17 
Higher resting-state functional connectivity between the subgenual and posterior 18 
cingulate cortices distinguished vulnerable adolescents remitted from preschool onset MDD 19 
from a HC group (Gaffrey et al. 2012). Treatment studies using resting-state fMRI in MDD 20 
have revealed a relationship between treatment response and pre-treatment connectivity to the 21 
sgACC (reviewed in (Dichter et al. 2014)). Whether patterns of sgACC resting-state 22 
functional connectivity, however, are distinctly altered in rMDD patients who will remain 23 
resilient compared with those who will go on to experience a recurrent MDE remains 24 
unknown. 25 
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We aimed to address this question by investigating whether resting-state functional 1 
connectivity to the sgACC could distinguish medication-free rMDD patients who would 2 
remain resilient over a 14 month follow up period from patients who would go on to 3 
experience a recurrent MDE and also from a HC group. It is important to underline that this 4 
study enrolled patients recovered from the depressed state and was therefore well-suited to 5 
identify physiological indices of sustained recovery, referred to here as resilience to recurrent 6 
MDEs, but not of resilience in general. Our aims were accomplished using a seed-based 7 
approach to analyze resting-state fMRI data acquired at the outset of study participation. The 8 
left anterior sgACC seed region was placed using coordinates described by Green and 9 
colleagues (2012) and was chosen for its close proximity to subgenual regions implicated in 10 
vulnerability to MDD (Green et al. 2012; Herringa et al. 2013; Workman et al. in press). We 11 
predicted that abnormal connectivity of the sgACC with a fronto-subcortical network would 12 
distinguish resilient from recurring episode MDD patients. More specifically, we predicted 13 
that lower connectivity of the sgACC would be observed in the resilient MDD patients 14 
compared to both the recurring episode MDD and HC groups. In other words, we predicted 15 
that the direction of connectivity in the resilient MDD patients would be the opposite to that 16 
reported in currently depressed patients, previously found to demonstrate hyperconnectivity 17 
of the sgACC (reviewed in (Dutta et al. 2014)). 18 
 19 
METHOD 20 
Participants 21 
This study received approval from the South Manchester National Health Service 22 
Research Ethics Committee (Ref No: 07/H1003/194) and all participants gave informed 23 
consent after the study procedures were explained in full (verbal consent for the telephone-24 
based screening and 3 month follow-up interviews and written consent at the start of each 25 
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study visit). The authors assert that all procedures contributing to this work comply with the 1 
ethical standards of the relevant national and institutional committees on human 2 
experimentation and with the Helsinki Declaration of 1975, as revised in 2008. Participants 3 
were recruited with online and print advertisements and received compensation for their time 4 
and travel expenses as part of the UK Medical Research Council-funded “Development of 5 
Cognitive and Imaging Biomarkers Predicting Risk of Self-Blaming Bias and Recurrence in 6 
Major Depression” project (Lythe et al. 2015; Zahn et al. 2015). A preliminary assessment of 7 
eligibility was conducted via telephone for 707 volunteers (a copy of the screening form is 8 
available at http://www.translational-cognitive-neuroscience.org/start/test-materials). The 276 9 
eligible volunteers following the telephone screening were invited to complete a clinical 10 
interview overseen by a senior psychiatrist (RZ). The 202 participants who agreed to the 11 
interview provided clinical and family histories, a urine sample for toxicology screening, and 12 
were assessed with the Structured Clinical Interview-I for DSM-IV-TR (SCID-I) to diagnose 13 
past MDEs and to detect current Axis I disorders (moderate to perfect inter-rater reliability; 14 
Table S1; (American Psychiatric Association 2000; First et al. 2002)). Of these, 48 HC 15 
participants and 96 rMDD patients were eligible to take part in the present study following 16 
the clinical interview. Thirty-nine HC participants subsequently underwent MRI scanning, 17 
though imaging data were excluded for one HC participant due to a pituitary abnormality, 18 
resulting in a final HC sample of N=38. Sixty-three rMDD patients underwent MRI scanning, 19 
though imaging data were excluded for 6 patients who did not complete the longitudinal 20 
study visits described below, resulting in a final patient sample of N=57. 21 
A detailed overview of the reasons for which participants were excluded is provided in 22 
Table S2. Inclusion criteria were: aged 18 to 65, right handed, English spoken as the native 23 
language, and normal or corrected-to-normal vision and hearing. Additional inclusion criteria 24 
for the rMDD group were: past MDE and MDD diagnosed by a senior psychiatrist (RZ) 25 
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according to DSM-IV-TR criteria (American Psychiatric Association 2000), International 1 
Classification of Diseases 10th Revision-diagnosed past moderate or severe MDE (World 2 
Health Organization 1992), and remission of symptoms at least 6 months prior to enrolment. 3 
Of note, the majority of MDD patients enrolled into this study had previously responded to 4 
psychological interventions or first-line antidepressants, with only a small fraction of patients 5 
having previously received treatment with second-line antidepressants (see Table 2). The 6 
MDD group was therefore predominantly comprised of patients with good treatment-7 
response, such as those seen in primary care, rather than the treatment-resistant patients 8 
typically seen in secondary care. Exclusion criteria were: current or relevant past Axis I 9 
disorders (e.g., history of substance abuse), psychotropic medication use within 4 weeks of 10 
enrolment (8 weeks for fluoxetine), acute suicidality/self-harming behaviours, impaired 11 
psychosocial functioning measured with the Global Assessment of Functioning scale 12 
(American Psychiatric Association 2000), a Montgomery-Åsberg Depression Rating Scale 13 
(MADRS) score >10 (Montgomery et al. 1979; Zimmerman et al. 2004), history of 14 
neurological or medical disorders affecting brain functioning, developmental disorders or 15 
learning disabilities, an Addenbrooke’s Cognitive Exam score <88 (conducted in participants 16 
aged over 50; (Mioshi et al. 2006)), and contraindications for MRI scanning. Additional 17 
exclusion criteria for the HC group were: history of Axis-I disorders, first-degree family 18 
history of mood disorders or schizophrenia. 19 
The rMDD patients completed follow up interviews via telephone or in person at 3, 6, 20 
and 14 months after enrolment using the MDD module and psychosocial functioning 21 
assessment from the Longitudinal Interval Follow-up Evaluation interview for DSM-IV 22 
(LIFE-IV; (Keller et al. 1987)). The LIFE interview includes a 6-point Psychiatric Status 23 
Rating (PSR): 1) no residual symptoms, 2) one or more mild symptoms causing no relevant 24 
distress or impairment, 3) mild symptoms causing no more than moderate distress or 25 
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impairment, 4) major symptoms not meeting full criteria for an MDE, and 5-6) major 1 
symptoms meeting criteria for an MDE. The raters were trained by the creators of the LIFE 2 
interview and inter-rater reliability was excellent (Table S1). Importantly, participation in the 3 
current study ended when patients developed a MDE. Of the 57 rMDD patients who 4 
completed the study, 30 remained in stable remission (resilient MDD group), 17 experienced 5 
a recurrent MDE (i.e., at least one MDE during the 14 month follow up period; recurring 6 
episode MDD group), and 10 developed symptoms not meeting full criteria for an MDE (i.e., 7 
a PSR of 3 requiring treatment or a PSR of 4; subthreshold symptom group). The analyses 8 
presented below include the resilient and recurring episode MDD groups, but exclude the 9 
subthreshold symptom group. 10 
The resilient MDD, recurring episode MDD, and HC groups were well-matched on 11 
demographic variables (Tables 1-2). The resilient and recurring episode MDD groups did not 12 
differ from the HC group on age, sex, or years of education. Compared to the HC group, 13 
however, scores on the Beck Depression Inventory (BDI; (Beck et al. 1996)) were higher in 14 
both the resilient (t(66)=2.96, p=0.004) and recurring episode MDD groups (t(53)=4.72, 15 
p<0.0001). BDI scores were also higher for the recurring episode MDD group compared to 16 
the resilient MDD group (t(45)=2.22, p=0.03). Nevertheless, average BDI scores for all 17 
groups were below 10 suggesting the presence of only minimal subthreshold depressive 18 
symptoms (Beck et al. 1988). Additionally, no group differences were observed for current 19 
scores on the MADRS. The resilient MDD group did not differ from the recurring episode 20 
MDD group on age, sex, education, past MDD subtype, average length of last MDE, months 21 
since remission, severity of the last MDE measured with the MADRS, months since last 22 
psychotropic use, number of patients previously treated, number of suicide attempts, or 23 
family history of MDD. The recurring episode MDD group did, however, have a greater 24 
number of previous MDEs compared with the resilient MDD group (t(45)=3.39, p=0.001). 25 
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 1 
Image acquisition 2 
MRI data were acquired on a 3T Philips Achieva scanner (Philips Medical Systems, 3 
Netherlands) with an 8-channel coil. A resting-state echo-planar image (EPI) was acquired 4 
for each participant using a sequence optimized for detecting ventral frontal signal (240 5 
volumes; 40 axial slices; 3mm slice thickness; ascending sequential acquisition; repetition 6 
time: 2000ms; echo time: 22ms; field of view: 240x240x120mm; acquisition matrix: 80x80 7 
voxels; reconstructed voxel size: 3mm3; flip angle: 90°). Participants were asked to lie 8 
motionless with eyes closed during the scan and were debriefed afterwards to confirm the 9 
instructions were followed, at which point we confirmed that no participants had fallen 10 
asleep. A 3-dimensional T1-weighted magnetization-prepared rapid-acquisition gradient-echo 11 
(MPRAGE) structural image was also acquired for each participant (160 axial slices; 0.9mm 12 
slice thickness; repetition time: 8.4ms; echo time: 3.9ms; field of view: 240x191x144mm; 13 
acquisition matrix: 256x163 voxels; reconstructed voxel size: 0.94x0.94x0.9mm; flip angle: 14 
8°). In order to rule out clinically significant neurological abnormalities, T2-weighted 15 
structural images were also acquired. 16 
 17 
Resting-state fMRI analysis 18 
The pre-processing pipeline for the resting-state fMRI data has been described in detail 19 
elsewhere (Workman et al. in press). Briefly, pre-processing was performed using SPM8 20 
http://www.fil.ion.ucl.ac.uk/spm/) for compatibility with the DPARSF Advanced Edition 21 
((Chao-Gan et al. 2010); http://rfmri.org/DPARSF) and Artifact Detection Tools (ART; 22 
http://web.mit.edu/swg/software.htm) MATLAB (MathWorks) toolboxes used in subsequent 23 
steps. For each EPI, the first 10 volumes were discarded, then slice timing and head motion 24 
correction were performed, and then regressors were created for high-motion volumes using 25 
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ART (framewise signal intensity >3 standard deviations from the global mean, framewise 1 
head displacement >1mm). Next, the MPRAGE images were co-registered to the EPIs and 2 
segmented, then linear detrending and nuisance covariates regression were performed on the 3 
EPIs (24 motion parameters [(Friston et al. 1996)], white matter and cerebrospinal fluid 4 
signal, ART regressors), and then the EPIs were normalized with parameters derived during 5 
segmentation. After this, the EPIs were smoothed with a 6mm kernel and band-pass filtered 6 
to preserve frequencies between 0.01Hz and 0.08Hz. High motion volumes identified by 7 
ART were then removed, as were sections of data spanning fewer than 5 contiguous volumes. 8 
All resulting EPIs contained at least 5 minutes of data (150 volumes). 9 
For each EPI, the average time course within a left anterior sgACC seed region was 10 
correlated with the time course of all other brain voxels, resulting in seed-based functional 11 
connectivity maps for each participant. The left anterior sgACC was chosen as the seed 12 
region because it was previously implicated in connectivity studies of rMDD patients 13 
(Montreal Neurological Institute [MNI] coordinates: -4, 23, -5; 6mm sphere; (Green et al. 14 
2012; Lythe et al. 2015; Workman et al. in press)), it is in close proximity to an anterior 15 
sgACC region which demonstrated abnormal resting-state functional connectivity in children 16 
vulnerable to MDD (MNI coordinates: 2, 23, -6; (Herringa et al. 2013)), and it is close to 17 
sgACC regions which demonstrate hyperconnectivity in current MDD patients (Dutta et al. 18 
2014). The resulting seed-based functional connectivity maps were then Fisher Z-transformed 19 
to improve normality. 20 
Next, we conducted a voxelwise analysis of variance (ANOVA) to compare the seed-21 
based functional connectivity maps from the resilient MDD, recurring episode MDD, and HC 22 
groups. Since we sought to identify a main effect of group, the analyses were carried out in 23 
SPM12 given that cluster-level familywise error (FWE) correction of F-tests cannot be 24 
performed in SPM8. We also used 7 bilateral a priori regions of interest (ROI) with known 25 
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structural or functional connections to the sgACC (Vogt et al. 1987; Carmichael et al. 1996; 1 
Kondo et al. 2003; Johansen-Berg et al. 2008) and which have been implicated in MDD 2 
(Elliott et al. 2011; Green et al. 2012) or social emotional and/or motivational processing 3 
(Moll et al. 2005; Zahn et al. 2009b; Elliott et al. 2011): ventromedial prefrontal cortex, 4 
anterior temporal cortex, amygdala, hippocampus, septal region, and hypothalamus. A 5 
detailed description of the creation of these ROIs has been provided elsewhere (Zahn et al. 6 
2009b; Workman et al. in press). 7 
Results were considered significant at an uncorrected voxel-level cluster forming 8 
threshold of p<0.001 and a cluster-level FWE-corrected threshold of p<0.05 across the whole 9 
brain and a priori ROIs. Mean correlation coefficients were extracted from each surviving 10 
cluster and entered into a one-way ANOVA with post-hoc Bonferroni pairwise comparisons 11 
to identify significant group differences in connectivity to the left anterior sgACC, and results 12 
were considered significant at p<0.05 two-tailed. 13 
 14 
RESULTS 15 
Main Effect of Group for Functional Connectivity 16 
Our analyses revealed a main effect of group (resilient MDD, recurring episode MDD, 17 
HC group) for connectivity of the left anterior sgACC seed region with the right anterior 18 
sgACC and with the left posterior sgACC (Table 3; Figure 1). The main effect of group was 19 
further reflected in the extracted cluster averages from both regions (right anterior sgACC: 20 
F(2,82)=14.0, p<0.0001; left posterior sgACC: F(2,82)=8.7, p<0.0004). Subsequent post-hoc 21 
Bonferroni-corrected pairwise comparisons showed lower connectivity between the seed 22 
region and the right anterior sgACC in the resilient MDD group (M=0.31, SD=0.14) 23 
compared to both the HC group (M=0.48, SD=0.12, p<0.001, mean difference=-0.17, 95% CI 24 
[-0.25,-0.09], d=1.30) and the recurring episode MDD group (M=0.42, SD=0.15, p=0.01, 25 
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mean difference=-0.12, 95% CI [-0.22,-0.02], d=0.76). In contrast, connectivity between the 1 
seed region and this right anterior sgACC region did not differ between the recurring episode 2 
MDD group (M=0.42, SD=0.15) and the HC group (M=0.48, SD=0.12, p=0.55, mean 3 
difference=-0.05, 95% CI [-0.15,0.04], d=0.44). A different pattern emerged for the left 4 
posterior sgACC region which, although showing lower connectivity with the seed region in 5 
the resilient MDD group (M=0.61, SD=0.22) compared with the HC group (M=0.81, 6 
SD=0.18, p<0.003, mean difference=-0.20, 95% CI [-0.31,-0.08], d=1.00), showed no 7 
difference between the resilient and  recurring episode MDD groups (M=0.71, SD=0.19, 8 
p=0.29, mean difference=-0.10, 95% CI [-0.24, 0.04], d=0.49). The recurring episode MDD 9 
group (M=0.71, SD=0.19) showed no significant differences from the HC group (M=0.81, 10 
SD=0.18, p=0.26, mean difference=-0.10, 95% CI [-0.24,0.04], d=0.54) in connectivity 11 
between the seed region and this left posterior sgACC region. Therefore, resting-state 12 
functional disconnection between the left and right anterior sgACCs, but not between the left 13 
anterior and posterior sgACCs, is an abnormality which distinguished the resilient MDD 14 
patients from the recurring episode patients. 15 
To our knowledge, this is the first study to investigate whether patterns of resting-state 16 
functional connectivity are capable of distinguishing between illness courses in young to 17 
middle-aged adults with rMDD. As a consequence, it was not possible to conduct a priori 18 
power analyses based on prior reports. Instead, post hoc power analyses were carried out 19 
using the effect sizes reported above at p=0.05, 2-sided. For connectivity between the seed 20 
region and right anterior sgACC, we achieved 99.95% power to detect differences between 21 
the resilient and HC groups and 68.58% power to detect differences between the resilient and 22 
recurring episode MDD groups. For connectivity between the seed region and left posterior 23 
sgACC, we achieved 98.00% power to detect differences between the resilient and HC 24 
14 
 
groups and 34.79% power to detect differences between the resilient and recurring episode 1 
MDD groups. 2 
 3 
Investigation of Potentially Confounding Variables 4 
Next, we investigated whether connectivity between the left and right anterior sgACCs 5 
was associated with BDI scores or number of previous MDEs, both of which were elevated in 6 
the recurring episode MDD patients relative to the resilient patients. Across the rMDD 7 
patients, however, connectivity between the left and right anterior sgACCs was not associated 8 
with BDI scores (rs=-0.11, p=0.47) or number of previous MDEs (rs=0.13, p=0.39). 9 
Furthermore, group differences in connectivity between the left and right anterior sgACCs 10 
remained significant for the resilient and recurring episode MDD patients after controlling for 11 
the effects of BDI scores (group difference adjusted for BDI scores: t(44)=3.44, p=0.001) and 12 
number of previous MDEs (group difference adjusted for number of previous MDEs: 13 
t(44)=2.61, p=0.01). Importantly, no group differences were observed in framewise 14 
displacement, a metric of relative head displacement between volumes (Power et al. 2012), 15 
suggesting the groups were well-matched for head motion (Table 1). 16 
 17 
DISCUSSION 18 
Main Findings and Interpretation 19 
Consistent with our general hypothesis, lower connectivity of the left anterior sgACC 20 
distinguished resilient from recurring episode MDD patients. Interestingly, the resilient MDD 21 
group showed abnormally low connectivity whilst the recurring episode MDD patients 22 
displayed no difference from the HC group. Intriguingly, we found lower interhemispheric 23 
sgACC connectivity to be distinctive of the resilient MDD patients. This pattern of lower 24 
functional connectivity was not explained by residual depressive symptoms, which indicates 25 
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that these results are not neural correlates of incomplete remission. Instead, the pattern of 1 
connectivity we have reported is sensitive to aspects of remission not captured by measures 2 
of residual symptoms. Furthermore, the recurring episode MDD patients had more previous 3 
MDEs than the resilient patients, as would be predicted by scar theories of depression 4 
vulnerability (Burcusa et al. 2007), but number of MDEs was not associated with 5 
interhemispheric sgACC connectivity. Our findings therefore confirm the significance of the 6 
sgACC to the pathophysiology of MDD by demonstrating for the first time that attenuated 7 
interhemispheric sgACC connectivity is associated with resilience to recurrent MDEs. 8 
Patients who are currently in the depressed state have repeatedly been shown to 9 
demonstrate increased connectivity to the sgACC that normalizes with treatment (reviewed 10 
by (Dichter et al. 2014; Dutta et al. 2014)). Findings from studies which investigated resting-11 
state connectivity to the sgACC in populations vulnerable to MDD are less consistent with 12 
respect to the direction of abnormal connectivity. For example, Gaffrey and colleagues 13 
(2012) described elevated resting-state connectivity between the subgenual and posterior 14 
cingulate cortices in patients with a history of preschool onset MDD. In contrast, Herringa 15 
and colleagues (2013) found that lower subgenual cingulate-hippocampal connectivity was 16 
associated with a history of childhood maltreatment, a known risk factor for MDD, in 17 
otherwise healthy adolescents. Our findings suggest abnormally low resting-state functional 18 
connectivity of the anterior sgACC may reflect a compensatory process in those patients who 19 
remain resilient to MDEs, similar to functional compensation mechanisms found in patients 20 
with brain lesions (Zahn et al. 2006). 21 
The lower interhemispheric sgACC connectivity we observed in the resilient MDD 22 
patients may appear to contradict studies which report normalization of resting-state sgACC 23 
functional connectivity and cerebral glucose metabolism with treatment (Dichter et al. 2014; 24 
Dunlop et al. 2014). These studies typically look at treatment-related changes in recently 25 
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remitted patients, however, in contrast to the patients studied here who were in stable 1 
remission (>6 months) at the time of scanning. The risk for experiencing a recurrent MDE is 2 
elevated during the first 6 months following remission from the depressed state (Solomon et 3 
al. 2000). If indeed the abnormally low interhemispheric functional connectivity of the 4 
anterior sgACC in resilient MDD patients observed here reflects a compensatory process, this 5 
may not emerge until later in the course of recovery. Normal functional connectivity to the 6 
anterior sgACC in the recurring episode MDD patients may reflect a failure to engage, or to 7 
continue engaging, this process. Alternatively, connectivity to the sgACC may be linearly 8 
associated with depression status, with connectivity to the sgACC ranging from abnormally 9 
high in currently depressed patients to abnormally low in patients who remain resilient to 10 
recurrent MDEs. Our findings also initially appear inconsistent with our previous 11 
interpretation of subgenual cingulate-amygdala resting-state functional disconnection as a 12 
primary vulnerability factor for melancholic MDD (Workman et al. in press). However, the 13 
pattern of lower subgenual cingulate-amygdala connectivity we observed in the melancholic 14 
MDD patients was independent of vulnerability or resilience to recurring MDEs (see 15 
Supplemental Results). We tentatively interpret this as supportive of our original 16 
interpretation of lower subgenual cingulate-amygdala connectivity as a signature of primary 17 
vulnerability to melancholia (Workman et al. in press), although this merits further 18 
investigation. 19 
To our knowledge, this is the first report of abnormalities in interhemispheric sgACC 20 
connectivity in MDD. Clues pertaining to the significance of this finding can be found in 21 
reports of psychosurgical interventions for MDD and in lesion studies. The subcaudate 22 
tractotomy (and the related limbic leucotomy), in which white matter is lesioned at a site 23 
below the caudate and posterior to the orbitofrontal cortex, was historically used to treat 24 
chronic MDD with moderate success (Schoene-Bake et al. 2010). A tractography study 25 
17 
 
conducted in healthy volunteers with a seed placed in the subcaudate tractotomy lesion site 1 
revealed fiber tracts spanning the left and right sgACCs (Schoene-Bake et al. 2010), 2 
suggesting disruption of these tracts may be related to clinical improvement in current MDD 3 
patients. Relatedly, chronic bilateral deep brain stimulation (DBS) applied to the white matter 4 
of the subgenual cingulate cortices in a treatment-resistant MDD group resulted in sustained 5 
remission in some patients (Mayberg et al. 2005). Although the exact mechanism by which 6 
DBS works has yet to be elucidated, the leading explanation is that inhibition occurs at the 7 
sites of stimulation (Mayberg et al. 2005). Patients with damage to the ventromedial 8 
prefrontal cortex, a large swathe of cortex along the medial wall of the frontal lobe which 9 
typically encompasses the subgenual cingulate, reported lower depression severity relative to 10 
a sample of control participants with damage to other brain regions (Koenigs et al. 2009). 11 
Furthermore, damage to the ventromedial prefrontal cortex has been associated with 12 
emotional deficits including diminished guilt (Koenigs et al. 2009), which may be excessive 13 
or overgeneralized in current MDD patients (American Psychiatric Association 2000). Taken 14 
together, damage to subgenual cingulate white matter pathways and to the ventromedial 15 
prefrontal cortices has previously been shown to modulate depressed mood as well as guilt, a 16 
distinctive symptom of MDD. The lower interhemispheric anterior sgACC connectivity we 17 
have reported in the resilient MDD group relative to the recurring episode MDD and HC 18 
groups is in keeping with these findings. 19 
 20 
Limitations and Future Directions 21 
The decision to use a seed-based approach to analyze our resting-state fMRI data 22 
entailed the selection of an a priori ROI which consequently constrained our results. This 23 
concern is mitigated, however, by the known importance of the sgACC to MDD as has been 24 
detailed throughout. Nevertheless, further functional connectivity investigations are needed to 25 
18 
 
determine whether resting-state networks not detected by our seed-based approach are also 1 
associated with resilience to recurrent MDEs. Given that the majority of patients enrolled into 2 
this study previously responded to treatment, it is also unclear whether the pattern of 3 
interhemispheric sgACC connectivity associated with resilience to recurrence can be 4 
generalized to remitted patients with a history of treatment resistance. Future research should 5 
seek to validate this signature of resilience to recurrence in patients with varying histories of 6 
treatment responsiveness. A general limitation of resting-state fMRI research is that is it not 7 
possible to control psychological processes whilst participants undergo scanning. Additional 8 
studies are needed to examine the psychological mechanisms underpinning attenuated 9 
interhemispheric sgACC connectivity which confers resilience to recurrence. Future 10 
longitudinal studies should also aim to replicate these findings and to investigate whether this 11 
signature can predict who will develop MDEs in populations without a history of MDD that 12 
are nonetheless vulnerable. 13 
 14 
Conclusions 15 
We demonstrated a distinctive pattern of attenuated interhemispheric resting-state 16 
sgACC connectivity in MDD patients resilient to recurrence. To our knowledge, this is the 17 
first resting-state fMRI signature of resilience to recurrence in patients who are remitted from 18 
the depressed state. The pattern of connectivity observed in the resilient MDD patients 19 
represents a potential target for therapeutic interventions aimed at improving resilience to 20 
future MDEs. 21 
22 
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FIGURE LEGENDS 1 
 2 
Figure 1. a) The network of regions demonstrating resting-state functional disconnection 3 
with the left anterior sgACC seed region in the resilient MDD patients. The solid arrow 4 
points to regions demonstrating functional disconnection in the resilient MDD patients 5 
compared to both the recurring episode MDD and HC groups. The dashed arrow points to 6 
regions demonstrating functional disconnection in the resilient MDD patients compared to 7 
the HC group only. Whole-brain images were cropped and displayed at an uncorrected voxel-8 
level threshold of p<0.001. b) Bar plots showing group differences in average Z-transformed 9 
correlation coefficients and standard errors for the right anterior sgACC cluster. HC, healthy 10 
control; L, left; MDD, major depressive disorder; R, right; sgACC, subgenual cingulate 11 
cortex.12 
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Table 1. Demographic variables in the recurring episode and resilient MDD patients and HC group 1 
 Recurring Episode 
MDD (N=17) 
Resilient 
MDD (N=30) 
HC 
(N=38) 
 Mean (SD) Mean (SD) Mean (SD) 
Age 35.9 (12.4) 37.6 (12.7) 36.2 (13.8) 
Years of Education 16.4 (2.6) 17.4 (2.0) 16.8 (2.3) 
BDI Scorea 5.2 (5.0) 2.6 (2.9) 0.9 (1.7) 
MADRS Score 0.9 (1.7) 0.8 (1.4) 0.7 (1.3) 
Sex (Male / Female) 6 / 11 12 / 18 13 / 25 
Framewise Displacement (mm) 0.26 (0.14) 0.24 (0.15) 0.24 (0.15) 
 2 
With the exception of BDI scores, the recurring episode MDD patients and HC group did not significantly differ on the demographic variables 3 
(Contingency Coefficient<0.02, p>0.93; t<0.62, p>0.53). Also with the exception of BDI scores, the resilient MDD patients and HC group did 4 
not significantly differ on the demographic variables (Contingency Coefficient<0.06, p>0.62; t<1.05, p>0.30). Again, with the exception of BDI 5 
scores, the recurring episode and resilient MDD patients did not significantly differ on the demographic variables (Contingency 6 
Coefficient<0.05, p>0.74; t<1.41, p>0.16). BDI, Beck Depression Inventory; HC, healthy control; MADRS, Montgomery-Åsberg Depression 7 
Rating Scale; MDD, major depressive disorder. 8 
aSignificantly different between the recurring episode MDD and HC groups (t(53)=4.72, p<0.0001), between the resilient MDD and HC groups 9 
(t(66)=2.96, p=0.004), and between the recurring episode and resilient MDD groups (t(45)=2.22, p=0.03).10 
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Table 2. Clinical characteristics of the recurring episode and resilient MDD patients 1 
 Recurring Episode 
MDD (N=17) 
Resilient 
MDD (N=30) 
 Mean (SD) Mean (SD) 
Past MDD subtype   
With melancholic features 9/17 17/30 
With atypical features 0/17 2/30 
No specific subtype 8/17 11/30 
Number of previous MDEs   
1 1/17 13/30 
2 5/17 5/30 
3 2/17 9/30 
4 4/17 1/30 
5 3/17 2/30 
6 or more 2/17 0/30 
Average number of previous MDEsa 3.7 (2.0) 2.1 (1.2) 
(range: 1–9) (range: 1–5) 
Last and most severe MDE details   
Average length of MDE (months) 17.7 (25.2) 15.3 (18.8) 
 (range: 1–96) (range: 1–81) 
Average time in remission (months) 21.5 (20.9) 37.9 (53.8) 
 (range: 6–72) (range: 6–282) 
Average MADRS score for MDE 34.6 (5.2) 35.1 (5.7) 
(range: 24–44) (range: 20–44) 
No psychotropic medication since 
(months) 
42.7 (54.4) 60.0 (86.5) 
(range: 2–173) (range: 3–372) 
Previous treatment   
SSRI antidepressant 15/17 25/30 
SNRI antidepressant 0/17 1/30 
Tricyclic antidepressant  0/17 2/30 
Mirtazapine 1/17 0/30 
Unknown class of antidepressant 3/17 3/30 
Benzodiazepines only 0/17 1/30 
No antidepressant medication 1/17 2/30 
CBT 6/17 6/30 
Self-guided CBT via internet, books 0/17 3/30 
Counselling 6/17 14/30 
Suicide attempts   
 0.18 (0.53) 0.20 (0.61) 
(range: 0–2) (range: 0–3) 
Lifetime axis-I comorbidityb   
Panic disorder with agoraphobia 1/17 0/30 
Bulimia nervosa 0/17 1/30 
No life-time co-morbidity 16/17 29/30 
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Family history   
First degree relative with MDD 10/17 16/30 
No family member with history of 
MDD 
6/17 11/30 
First degree relative with schizophrenia 
or bipolar disorder 
1/17 3/30 
 1 
All MDD patients stopped medication before the required washout phase. Means and 2 
standard deviations are reported and/or the number of cases. Recurring episode and resilient 3 
MDD patients did not significantly differ on past MDD subtype, average length of the last 4 
MDE, average time in remission, average MADRS score for the last MDE, average time 5 
since last taking psychotropic medications, number of patients previously treated, number of 6 
suicide attempts, lifetime axis-I comorbidity, or family history (Contingency 7 
Coefficient<0.20, p>0.18; t<1.21, p>0.23). There were also no differences between the 8 
resilient and recurring episode MDD patients regarding previous treatment with SSRIs, 9 
SNRIs, tricyclics, mirtazapine, or CBT (Contingency Coefficient<0.20, p>0.17). CBT, 10 
cognitive behavioural therapy; MADRS, Montgomery-Åsberg Depression Rating Scale; 11 
MDD, major depressive disorder; MDE, major depressive episode; SSRI, selective serotonin 12 
reuptake inhibitor; SNRI, serotonin norepinephrine reuptake inhibitor. 13 
aSignificantly different between the recurring episode and resilient MDD groups (t(45)=3.39, 14 
p=0.001). 15 
bAll co-morbid disorders were fully remitted at the time of study and none were likely to be 16 
the primary cause of the depressive episodes. 17 
 18 
28 
 
Table 3. Regions significant for a main effect of group (recurring episode MDD, resilient MDD, HC group) for functional connectivity to the 1 
left anterior subgenual cingulate cortex seed region 2 
Hemisphere Regions 
Peak MNI 
Coordinates Peak Cluster FWE-Corrected 
X Y Z z Score Size p Value 
R Anterior subgenual cingulate cortex 9 21 -12 4.03 22 0.039a,b 
L Posterior subgenual cingulate cortex -6 15 -3 3.20 4 0.043c,d 
 3 
FWE, familywise error; HC, healthy control; L, left; MDD, major depressive disorder; MNI, Montreal Neurological Institute; R, right; ROI, 4 
region of interest. 5 
aFWE-corrected at the cluster-level over an a priori ventromedial prefrontal cortex ROI. 6 
bLower connectivity with the seed region in the resilient MDD patients (M=0.31, SD=0.14) compared to both the recurring episode MDD 7 
(M=0.42, SD=0.15, p=0.013, mean difference=-0.12, 95% CI [-0.22,-0.02], d=0.76) and HC groups (M=0.48, SD=0.12, p<0.0001, mean 8 
difference=-0.17, 95% CI -0.25,-0.09], d=1.30). 9 
cFWE-corrected at the cluster-level over an a priori septal region ROI. 10 
dLower connectivity with the seed region in the resilient MDD patients (M=0.61, SD=0.22) compared to the HC group (M=0.81, SD=0.18, 11 
p<0.0003, mean difference=-0.20, 95% CI [-0.31,-0.08], d=1.00) but not the recurring episode MDD group (M=0.71, SD=0.19, p=0.29, mean 12 
difference=-0.10, 95% CI [-0.24,0.04], d=0.49). 13 
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Supplemental Results 8 
In an earlier cross-sectional resting-state fMRI study which included the participants 9 
studied here, our group found subgenual cingulate-amygdala resting-state functional 10 
disconnection to be distinctive of remitted depressed patients with a history of melancholic 11 
major depressive episodes (MDE) compared to non-melancholic and healthy control groups 12 
(Workman et al. in press). We argued that subgenual cingulate-amygdala functional 13 
disconnection is a signature of primary vulnerability for melancholic major depressive 14 
disorder (MDD). In view of the present findings suggesting lower interhemispheric 15 
connectivity between the subgenual cingulate cortices promotes resilience to recurring 16 
MDEs, we wanted to determine whether the network of lower connectivity we previously 17 
observed in the melancholic remitted MDD (rMDD) patients is better understood as 18 
promoting resilience. To this end, we first extracted the mean Fisher Z-transformed 19 
correlation coefficients from the amygdala cluster as described previously (Workman et al. in 20 
press) for each participant in the current study. These data were then entered into a two-way 21 
ANOVA in SPSS 20 with between-subjects factors for group (resilient or recurring episode 22 
MDD) and for subtype (melancholic or non-melancholic). Results were considered 23 
significant at p<0.05 two-tailed. 24 
For subgenual cingulate-amygdala resting-state connectivity, we observed a main 1 
effect of subtype (F(1,43)=7.1, p=0.01) but no main effect of group (F(1,43)=0.001, p=0.97) 2 
and no subtype by group interaction (F(1,43)=0.33, p=0.57). Subsequent post-hoc pairwise 3 
comparisons revealed lower subgenual cingulate-amygdala connectivity in the melancholic 4 
rMDD group (M=0.12, SD=0.17) compared to the non-melancholic rMDD group (M=0.25, 5 
SD=0.11, p=0.01, mean difference=-0.12, 95% CI [-0.21,-0.03]). These results suggest the 6 
network of lower functional connectivity we previously reported in the melancholic rMDD 7 
patients is independent of vulnerability or resilience to recurring MDEs, which is in keeping 8 
with our original interpretation of subgenual cingulate-amygdala functional disconnection as 9 
a primary vulnerability factor for melancholia. 10 
  11 
Table S1. Inter-rater reliability for the SCID-I, MADRS, and PSR scales 1 
 SCID-I 
subtype 
Current 
MADRS 
MADRS 
previous MDE 
Current 
PSR 
Highest PSR 
during follow-up 
Raters Kappa Value ICC Value ICC Value ICC Value ICC Value 
RZ & KL 0.60 0.63 0.45 0.96 0.98 
RZ & JG – 0.91 0.80 – – 
KL & JG 1.00 0.86 0.80 – – 
KL & CW – – – 0.96 0.99 
Mean 0.80 0.80 0.68 0.96 0.98 
 2 
Reliability for the SCID-I mood disorders module subtype diagnosis is given as a kappa 3 
value. Reliability for the MADRS and PSR are given as intra-class correlation (ICC) values 4 
(two-way mixed with absolute agreement). RZ, KL, and JG completed the recommended 5 
training for the SCID-I for DSM-IV-TR, and RZ, KL, and CW completed the recommended 6 
training for the PSR. The SCID-I was modified to allow lifetime diagnoses of MDD 7 
subtypes, including melancholic and atypical specifiers. The MADRS was used to assess 8 
depression severity at the time of the clinical interview, and was modified to allow for 9 
retrospective assessment of the last and most severe MDE. The PSR was used to assess the 10 
severity of and impairment caused by depressive symptoms present at each follow up 11 
interview and retrospectively throughout the follow up period. The Kappa values for the 12 
SCID-I subtype diagnoses reflect moderate to perfect agreement (Landis et al. 1977), and 13 
ICC values for the MADRS (both current and previous MDE) and PSR reflect moderate to 14 
excellent agreement (Fleiss 1986). ICC, intra-class correlation; MADRS, Montgomery-15 
Åsberg Depression Rating Scale; MDD, major depressive disorder; MDE, major depressive 16 
episode; PSR, Psychiatric Status Rating; SCID-I, Structured Clinical Interview-I. 17 
Table S2. Reasons for exclusion of volunteers from the current study 1 
Reasons for Exclusion N 
Telephone Screening 
MRI contraindications 77 
Psychiatric disorders other than MDD 54 
Current antidepressants or other centrally active medications 52 
Withdrawal after telephone screening 33 
Not meeting full screening criteria for MDD 30 
Family history of MDD/bipolar/schizophrenia (HC group) 26 
Substance or alcohol abuse 23 
Current antihypertensive or statin medications 20 
Left-handed 20 
Non-native English speaker 19 
Thyroid function problems 19 
Fulfilling criteria for current MDD 13 
History of cancer 7 
Not remitted for long enough (>6 months) 7 
Epilepsy 5 
No reason recorded 5 
Other general medical conditions 5 
Diabetes 4 
Out of age range (18 – 65 years) 4 
Excluded because of age-matching (HC group) 3 
Multiple sclerosis 3 
History of stroke 1 
Vitamin D deficiency 1 
Total excluded after the telephone screening 431 / 707 
Clinical Interview (remitted MDD patients) 
Unable to schedule for additional visits 10 
Fulfilling criteria for a bipolar disorder 6 
Fulfilling criteria for current social anxiety disorder 6 
Not meeting full criteria for MDD 5 
Fulfilling criteria for past substance abuse 4 
Not remitted for long enough (>6 months) 3 
Residual symptoms of post-traumatic stress disorder 3 
Probable personality disorders 2 
Fulfilling criteria for current generalized anxiety disorder 1 
MRI contraindications 1 
Withdrawal after the clinical interview 1 
Total number of remitted MDD patients excluded after the clinical interview 42 / 138 
Clinical Interview (HC group) 
Unable to schedule for additional visits 6 
Probable or definite positive first degree family history of MDD 4 
Fulfilling criteria for a past MDE lasting less than two months 1 
Fulfilling criteria for current adjustment disorder 1 
Fulfilling criteria for current MDD 1 
Fulfilling criteria for current social anxiety disorder 1 
Non-native English speaker 1 
Past depressive episode not fulfilling criteria for a past MDE 1 
Total number of HC participants excluded after the clinical interview 16 / 64 
 1 
Of the 707 volunteers who completed the telephone screening, 276 were eligible (184 2 
remitted MDD patients, 92 HC participants). Of these, 202 participants agreed to complete 3 
the clinical interview after having reviewed the study’s participant information sheet (138 4 
remitted MDD patients, 64 HC participants). Following the clinical interview, 144 5 
participants were eligible to complete the remaining study visits (96 remitted MDD patients, 6 
48 HC participants). Of these, 102 participants underwent resting-state fMRI scanning (63 7 
remitted MDD patients, 39 HC participants). fMRI, functional magnetic resonance imaging; 8 
HC, healthy control; MDD, major depressive disorder; MDE, major depressive episode. 9 
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